LAS VEGAS and VANCOUVER, British Columbia, July 19, 2022 (GLOBE NEWSWIRE) -- TAAT® GLOBAL ALTERNATIVES INC. (CSE: TAAT) (OTCQX: TOBAF) (FRANKFURT: 2TP) (the “Company” or “TAAT®”) is pleased to announce its initial schedule of investor events for the next twelve months hosted by TAAT® CEO Michael Saxon and CFO Joel Dumaresq. Each event will follow the Company’s quarterly fiscal reporting periods and will primarily consist of discussion by management of financial results and material business developments from the preceding fiscal quarter. In addition, the Company will solicit questions from investors prior to each event to be addressed by management. The current schedule of quarterly investor events is provided below.
TAAT® Chief Executive Officer Michael Saxon commented, “I consider it essential for shareholders to have access to open and transparent communication with management and our first event of 2022 earlier this month was just the start. Today’s announcement builds on my promise made during that call to provide updates on a quarterly basis. I look forward to our upcoming event in September during which we will share more details about the two ‘focus’ markets we have prioritized for TAAT®.”
| Reporting Period | Date of Investor Event | Event Start Time |
| Fiscal Q3 2022 (three-month period ended July 31, 2022) | Thursday, September 22, 2022 | 4:15 pm Eastern |
| Fiscal Q4 2022 (three-month period ended October 31, 2022) | Thursday, December 15, 2022 | 4:15 pm Eastern |
| Fiscal Q1 2023 (three-month period ended January 31, 2023) | Monday, March 20, 2023 | 4:15 pm Eastern |
| Fiscal Q2 2023 (three-month period ended April 30, 2023) | Thursday, June 15, 2023 | 4:15 pm Eastern |
Please note that all dates and times are subject to change, and any such adjustments will promptly be iterated to investors using standard communication channels. Registration information and links will be provided well in advance of each investor event.
An audio recording of the July 6, 2022 TAAT® investor teleconference can be accessed on the Company’s YouTube channel through the following link: https://www.youtube.com/watch?v=quguVqd-2EY
On behalf of the Board of Directors of the Company,
TAAT® GLOBAL ALTERNATIVES INC.
“Michael Saxon”
Michael Saxon, CEO and Director
For further information, please contact:
TAAT® Investor Relations
1-833-TAAT-USA (1-833-822-8872)
investor@taatglobal.com
THE CANADIAN SECURITIES EXCHANGE (“CSE”) HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE, NOR HAS OR DOES THE CSE’S REGULATION SERVICES PROVIDER.
About TAAT® Global Alternatives Inc.
TAAT® develops, manufactures, and distributes alternative products in categories such as tobacco, hemp, kratom, and other emerging segments of the CPG industry. Its flagship product is a nicotine-free/tobacco-free combustible with a patent-pending base material formulation, sold in over 2,700 U.S. stores. With over CAD $80 million in overall net revenue in 2021, TAAT®’s facilities include a manufacturing plant in Nevada, as well as a distribution centre and multiple convenience stores in Ohio.
For more information, please visit http://taatglobal.com.
Forward-Looking Statements
This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Often, but not always, forward-looking information and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur, or be achieved. Forward-looking information in this news release includes statements regarding the anticipated performance of TAAT® in the tobacco industry, in addition to the following: Anticipated occurrence of the four TAAT® investor events listed in the press release, and any potential impacts from the occurrence of such investor events. The forward-looking information reflects management’s current expectations based on information currently available and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those discussed in the forward-looking information. Although the Company believes that the assumptions and factors used in preparing the forward-looking information are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed timeframes or at all. Factors that could cause actual results or events to differ materially from current expectations include: (i) adverse market conditions; (ii) changes to the growth and size of the tobacco markets; (iii) changes to the regulatory landscape applicable to the Company's business; and (iv) other factors beyond the control of the Company. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Company’s management to predict all risk factors, nor can the Company assess the impact of all factors on Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any forward-looking information. The forward-looking information included in this news release are made as of the date of this news release and the Company expressly disclaims any intention or obligation to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by applicable law.
The statements in this news release have not been evaluated by Health Canada or the U.S. Food and Drug Administration. As each individual is different, the benefits, if any, of taking the Company’s products will vary from person to person. No claims or guarantees can be made as to the effects of the Company’s products on an individual’s health and well-being. The Company’s products are not intended to diagnose, treat, cure, or prevent any disease.
This news release may contain trademarked names of third-party entities (or their respective offerings with trademarked names) typically in reference to (i) relationships had by the Company with such third-party entities as referred to in this release and/or (ii) client/vendor/service provider parties whose relationship with the Company is/are referred to in this release. All rights to such trademarks are reserved by their respective owners or licensees.
Statement Regarding Third-Party Investor Relations Firms
Disclosures relating to investor relations firms retained by TAAT® Global Alternatives Inc. can be found under the Company's profile on http://sedar.com.
